Diffusion Pharmaceuticals Inc (DFFN)

[glens0]

OUTLOOK
On March 21, 2022, Diffusion Pharmaceuticals, Inc. (DFFN)
announced financial results for the fourth quarter and full year
2021 and provided a business update. The company intends to
develop its lead compound, trans sodium crocetinate (TSC), for
the treatment of hypoxic solid tumors. Diffusion will be filing a
study protocol with the U.S. FDA and we anticipate a trial
initiating in the second half of 2022, subject to FDA feedback and
the availability of study drug. In the interim, the company has
initiated two additional oxygenation trials – 1) the Altitude Trial is
investigating the consumption of oxygen in the presence of TSC
in a simulated high altitude environment; and 2) The ILD-DLCO
is a double-blind, randomized, placebo controlled study to
evaluate the effects of TSC on diffusion of carbon monoxide
through the lungs (DLCO) of patients with interstitial lung
disease. Results for the Altitude Trial should be available in mid2022, while results for the ILD-DLCO trial should be available in
the second half of 2022.